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Material and Methods: Between January and December 2014, 
29 patients with locally advanced cervical cancer were 
underwent combination external beam radiotherapy with or 
without concomitant chemotherapy and IGBT with or without 
hybrid technique using VariSourceTM ring applicator with 
‘Siriraj Ring Cap’ extension (at least one fraction). 117 
dosimetric planning and clinical outcome of treatment were 
evaluated. 
 
Results: For high risk clinical target volume (HR CTV) the 
median was volume 37.4 cm3 (range; 15.3-76.1 cm3) and the 
median of D90 was 85.3Gy (range; 76.4-90.5Gy). The median 
of D2cc for bladder, rectum, sigmoid, and bowel loop were 
84Gy (range; 68.3-89.7Gy), 66.1Gy (range; 56.8-76.3Gy), 65.6 
(range; 49-77.1Gy), and 61.9Gy (range; 45.8-78.1Gy), 
respectively. 81.2% (95 of 117 plans) were performed using 
VariSourceTM ring applicator with ‘Siriraj Ring Cap’ 
extension, while mean of coverage of the HR CTV was 89.2% 
(range; 57-99%). 18.8% (22 of 117 plans) were applied using 
tandem with ovoids, and mean of coverage of the HR CTV 
was 79.9% (range; 53-96%). Median follow up was 10.6 
months. The actuarial 1 year loco-regional recurrence free 
survival rate was 90.5% (95% confidence interval (CI); 67-
98%), progression free survival rate was 85.7% (95% CI; 62-
95%), and overall survival rate was 95.4% (95% CI; 71-99%). 
One patient had a grade 2 late rectal complication. No grade 
3-5 late complications have been recorded so far. 
 
Conclusion: IGBT with or without hybrid technique using 
VariSourceTM titanium ring applicator with ‘Siriraj Ring Cap’ 
extension is applicable for locally advanced cervical cancer 
resulting in an excellent local control rate and limited 
morbidity. 
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Purpose or Objective: The effectiveness of radiation therapy 
in the management of cervical cancer of all stages is well 
established. Radiation therapy usually consists of a 
combination of external beam therapy and brachytherapy. 
Further exploration of new approaches and methodologies is 
a promising direction of development. Given the 
radiobiological aspects and an important economic factor, 
i.e. reduction of hospital stay. The aim of this study was to 
estimate the effectiveness of the treatment of cervical 
cancer patients using adaptive image-guided brachytherapy 
(IGBT) during split course. 
 
Material and Methods: In the period from May 2014, 38 
patients with primary cervical cancer were treated with 
combined radiotherapy using the new split-adaptive 
methodology for IGBT. We used conformal radiation 
techniques: BOX method, IMRT or RapidArc. Total dose on the 
pelvic area and regional metastases was 50 Gy. Further HDR 
IGBT brachytherapy was followed with dosimetry planning 
MRI - images. The treatment was on 1st and 2nd , 8th and 9th 
days, ring tandem applicators implantation under general 
anesthesia. Between the fractions 1 and 2 and 3 and 4, the 
patients were with applicator under the supervision of 
medical staff during the day. Monitoring planning was 
conducted according to MRI-studies; as a result treatment 
plan was composed for every 2 fractions. The position of the 
applicator in relation to the tumor and critical organs during 
the day doesn’t change provided that the methodology is 
being correctly observed. Dose plans were optimized for 
maximal tumor dose (D90) and coverage (V100 and V80). The 
dose parameters in the target volume are the following: D 90 
= 7.3 (5.9-9.1) Gy, V 100 = 91.5 (79.2-99.1) %, V 80 = 97.8 
(90.5 -100). Of the patients it was T2bN0M0 – 7 patients, 
T3bN0M0 – 5, T2b-3bN1M0 – 18, T2b-3bN1M1 – 8. 
 
Results: in the results the values of dose rates (D 2 cc / D 0,1 
cc) to organs of risk (bladder, rectum and sigmoid) are the 
following: 3.7 (1.7-7) / 4.8 (2.2 -9.4) Gy; 3.1 (1.2-6) / 4.2 
(1.4 - 8.3) and 3.9 (2.2-5.7) / 5.5 (3.5 -7.6) Gy. During 
follow-up time for 12 months no any acute or late toxicity of 
grade 2 were observed and not observed any difference in 
comparison with the fractionation scheme used previously. 
No one local recurrence were observed, regional recurrence 
in 2 (2 and 7 months), distant metastasis in 1 (12 months). 
The patients have undergone the treatment satisfactorily. 
The number of surgical implantations decreases from 4 to 2. 
According to preliminary data, local radiation reactions are 
not multiple. 
 
Conclusion: The main advantage of this method is the dose 
delivery in a shorter period of time, which allows for a 
greater control of the tumor. This method allows to reduce 
the time of course of brachytherapy to 9 days. Evaluating the 
effectiveness of treatment shows good tolerance of this 
treatment with satisfactory results. This clinical study is 
currently ongoing. 
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Purpose or Objective: To evaluate dosimetric and clinical 
findings of MRI-guided HDR brachytherapy (HDR-BQ) for 
cervical carcinoma. 
 
Material and Methods: From 2008 to 2014: 50 patients. All 
patients had a CT, MRI and pelvic-paraaortic 
lymphadenectomy. Treatment: pelvic(+/-)para-aortic3D/IMRT 
radiotherapy(45Gy) and weekly cisplatin followed by HDR-BQ 
and pelvic node/ parametrial boost 60Gy. Two implants at 
week 6th and 7 th were done: 5 fractions of 6Gy and from 
2011 4 fractions of 7Gy. MRI/TAC was done in each implant. 
There where defined: GTV, CTH-HR, CTV-IR; OAR: rectum, 
bladder and sigmoid. 
 
Results: Patients: T1b2-T2a: 3p, T2b 36p, T3a: 2p; T3B 9p; 
N0: 31p, N1 19p.With a median follow up of 50.6 months(8.1 
– 89.2 months), 5 patients had local recurrence, 6 lymph 
node recurrence, 6 distant metastasis and 36 without 
recurrence. Local control at 5 years was 88%; Ib2-IIB: 93%, III: 
70%. (p:0.07). Lymph node Regional Disease Free 
Survival(RDFS) 5y was 88%; IB2-IIB: 89%, III: 83% (p:ns); for 
pN0: 94%; pN+ iliac-paraaortic: 77% (p: 0.08). Metastasis Free 
Survival 5y was 78%; IIBN0: 78%, IIBN1: 89%, III: 63%. Overall 
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survival(OS) at 3 years was 82% and at 5 years was 63%; IB2-
IIB 5yr: 70%; III 5yr: 27% (p: 0.01); For pN0 5yrs 74%; pN+ 
iliac-paraortic 5yr: 45% (p: 0.03).  
Dosimetric parameters: D90<6-7Gy(prescription dose) in 5p 
before 2011(since then interstitial implants were associated 
in 47%). The Local RFS: D90< 6Gy 87%, D90> 6Gy: 90% (p:ns); 
OS: D90< 6Gy 58%, D90> 6Gy: 67% (p:ns). D2cc-Sigma: 1.7-6.2 
Gy (md 3.8 Gy); D2cc-rectum: 2-6.1 (md 4.2); D2cc-bladder 
3.4-5.7 (md5.25). 
 
Conclusion: Use of intersticial HDR-BQ guided by RM 
increased CTV-HR dose and local control , like EMBRACE 
results. Nodal boost improves RDFS and perhaps OS. 
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Purpose or Objective: To elaborate the application of self-
made applicator which invented by our department (Patent 
No: 201420583680.X) in brachytherapy for recurrent cervical 
cancer at vaginal residue. This study especially pays 
attention to the doses evaluation of GTV and the OARs in 
brachytherapy by this technical.  
 
Material and Methods: 14 patients from 2013-2014 in our 
hospital who suffered from recurrent cervical cancer at 
vaginal residue in 0.5-3.5 years after radical hysterectomy 
and external beam radiotherapy (45 Gy/25 fractions) 
±chemotherapy ±brachytherapy were treated with MRI based 
and ultrasound guided brachytherapy using the self-made 
applicator. The self-made applicator was made of silica balls 
in matrix distribution connecting with a hole in front and 
behind it, making it formed into a straight line. The diameter 
of silica ball is 1 cm, the aperture of the hole is 1.5 mm. 
Therefore this self-made applicator could provide with the 
needle inserting smoothly and tidy and the depth of the 
needle can be adjusted. Moreover, this applicator can be 
used by superposition of multilayer, so it could be easily 
adapted to any shape. The prescribed dose of brachytherapy 
was 7 Gy×3-6 fractions, one week apart was planned. The 
GTV included the tumor, the CTV comprised the GTV with a 
10 mm circumferential margin and OARs were delineated. 
And then we recorded the GTV D90, D100 and D2cc of 
rectum, small intestines, bladder and sigmoid colon under 
the self-made applicator. 
 
Results: After plenty years of using the conventional 
applicators in brachytherapy, we found the radical 
hysterectomy cause the vaginal cuff end stenosis, the top of 
the conventional applicator, such as the Utrecht intertitial 
applicator cannot get close to the cancer region well which 
tumor invaded towards pelvic, so it was unable to achieve a 
high dose to the tumor, or it may induce an excess dose to 
normal tissues. In this research, we found the self-made 
applicator showed a high GTV dose and an acceptable OARs 
dose. Specifically, the GTV D90 and D100 for using self-made 
applicator were 724±64 cGy and 436±39 cGy, and the average 
D2cc for rectum, sigmoid colon and bladder was 370±21, 
265±16 and 423±44 cGy, the total dose when transformed to 
EQD2 models was under the constraints.  
 
Conclusion: The self-made applicator show excellent dose 
parameters on dose coverage and sparing exposure to OARs, 
which was more beneficial to the recurrent cervical cancer at 
vaginal residue invaded towards pelvic.  
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Purpose or Objective: Concomitant chemo-radiation and 
intracavitary brachytherapy (BT) is the standard treatment 
for locally advanced cervical carcinoma. In an our previous 
experience we reported the feasibility of [18F]FDG-PET in the 
BT treatment planning as functional imaging technique able 
to visualize neoplastic tissue. The purpose of this analysis 
was to evaluate, after an adequate follow-up, the site of 
recurrence and,in case of local relapse , if it was PET positive 
during BT. Survival and the late toxicity were also analysed. 
 
Material and Methods: From June 2007 to May 2010, thirteen 
women with locally advanced cervical carcinoma were 
enrolled into the study. All patients underwent external 
beam radiation therapy (EBRT) to whole pelvis (box 
technique to a total dose of 50.4 Gy) with weekly 
concomitant cisplatinum chemotherapy. HDR BT was 
performed weekly (5 Gy per fraction; 5 to 6 fractions). All BT 
fractions were planned by CT scan and, in the first and in the 
fourth fraction, FDG-PET/CT was also employed. Local 
control rate, progression free survival, overall survival and 
treatment related toxicities under RTOG criteria were 
evaluated 
 
Results: At the median follow-up of 61 months, the 
estimated 5-year progression-free survival (PFS) and the 5-
year overall survival (OS) were 56% and 70% respectively. The 
5-year local control rate was 84.6%. Only one patient had a 
local relapse corresponding to a PET positive area in BT 
guided planning. No G3-4 acute or late gastrointestinal or 
genitourinary toxicity has been recorded . 
 
Conclusion: In our experience, PET in BT planning of the 
cervical carcinoma gives some added useful information. The 
main goal of our analysis remains to define the site of 
possible recurrence: the recognition of a local relapse in PET 
positive area may suggest the opportunity of dose escalation 
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Purpose or Objective: To evaluate clinical outcomes and 
acute/late toxicities in patients with locally advanced 
cervical cancer treated with chemotherapy (CT) and external 
beam radiation therapy (EBRT), followed by high-dose rate 
brachytherapy (HDR-BRT) delivered with the Fletcher-
Williamson tandem and ovoid applicator 
 
Material and Methods: we evaluated 40 patients, median age 
57 years (range 40-83), treated between January 2007 and 
October 2014. According to FIGO classification, 10% were 
stage IB, 7,5% IIA, 45% IIB, 5% IIIA, 27,5% IIIB, 5% IV. All 
patients underwent pelvic +/- paraaortic EBRT (10/40 
patients); following the GEC-ESTRO recommendations, 
fractionation scheme for pelvic irradiation was 45-50.4 Gy in 
25-28 daily fractions (1.8 Gy/fr). The addition of a 
parametrial boost (10 Gy in 5 daily fractions) was performed 
in 10/40 patients (25 %). BRT with Fletcher applicator was 
performed in all patients after EBRT, with the fractionation 
scheme 22,5 Gy in 5 fractions (twice a day with 6 hours inter-
fraction interval). Concomitant CT was administrated in all 
patients, neoadjuvant CT was administrated in 15%. 
Treatment related toxicity was evaluated weekly during 
therapy and at each follow-up control, using RTOG/EORTC 
Radiation Morbidity Criteria. Response was investigated with 
periodical cervical cytology and CT scans; every treatment 
was evaluated in terms of BED10 and EQD2, with a median 
BED10 of 90.43 Gy (range 75.5-104.1) and median EQD2 of 
75.33 Gy (range 86.7-62.9). 
 
Results: With a median follow-up of 30 months (range 12-87), 
we observed acute/late genitourinary and gastrointestinal 
toxicity ≥ grade 2 in 10 % of patients, including one G4 GI 
acute toxicity (diarrhea requiring parenteral support) 
